The value of lipid metabolites 9,10-DOA and 11,12-EET in prenatal diagnosis of fetal heart defects

Aims: To explore the maternal metabolic changes of fetal congenital heart disease (FCHD), and screen metabolic markers to establish a practical diagnostic model.Methods: Maternal peripheral serum from 17 FCHD and 63 non-FCHD pregnant were analyzed by Ultra High-performance Liquid Chromatography-Mass/Mass (UPLC-MS/MS).Results: In the FCHD and the non-FCHD, 132 metabolites were identified, including 35 differential metabolites enriched in the purine, caffeine, primary bile acid, and arachidonic acid metabolism pathway. Finally, the screened (+/-)9,10-dihydroxy-12Z-octadecenoic acid (AUC = 0.888) and 11,12-epoxy-(5Z,8Z,11Z)-icosatrienoic acid (AUC = 0.995) were incorporated into the logistic regression model. The AUC value of the two-metabolite model was 1.0, superior to proline (AUC = 0.867), uric acid (AUC = 0.789), glutamine (AUC = 0.705), and taurine (AUC = 0.923) previously reported. The clinical decision curve analysis (DCA) showed the highest clinical net benefit of the model, and internal validation by bootstrap shows the robustness of the model (Brier Score = 0.005).Conclusion: For the prenatal diagnosis of CHD, our findings are of great clinical significance. As an additional screening procedure, the identification model might be used to detect.

Automated summary

The study aimed to explore maternal metabolic changes in fetal congenital heart disease (FCHD) and screen metabolic markers to establish a practical diagnostic model. Maternal peripheral serum samples from 17 FCHD and 63 non-FCHD pregnant women were analyzed using UPLC-MS/MS. The study identified 132 metabolites, including 35 differential metabolites enriched in various metabolic pathways. Two metabolites, (+/-)9,10-dihydroxy-12Z-octadecenoic acid and 11,12-epoxy-(5Z,8Z,11Z)-icosatrienoic acid, were incorporated into a logistic regression model, which showed superior diagnostic performance compared to previously reported markers.